FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
Entity
UAM. Departamento de MedicinaPublisher
Biomed Central Ltd.Date
2021-02-12Citation
Breast Cancer Research 23.1 (2021): 21ISSN
1465-542XFunded by
MQF is a recipient of the following grants: AES - PI16/00354 and AES – PI19/00454 funded by the ISCIII (Instituto de Salud Carlos III, Ministry of Science and Innovation, Spain) and co-funded by the European Regional Development Fund (ERDF); 2017/BMD3733 - Call for Coordinated Research Groups from Madrid Region - Madrid Regional Government - ERDF funds. RC and MJB are co-recipients of an AES – PI17/01865 grant funded by the ISCIII and co-funded by the European Regional Development Fund (ERDF). RC is a recipient of funding PIE15/00068, PI20/01458, and PT17/0017/0007 by the ISCIII. This study was partially funded by Bayer Inc. CRIS Contra el Cancer Foundation contributed with a generous donation to this studyEditor's Version
https://doi.org/10.1186/s13058-021-01398-8Subjects
MedicinaNote
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliationsRights
© The Author(s)Abstract
Background
FGFR1 amplification, but not overexpression, has been related to adverse prognosis in hormone-positive breast cancer (HRPBC). Whether FGFR1 overexpression and amplification are correlated, what is their distribution among luminal A or B HRPBC, and if there is a potential different prognostic role for amplification and overexpression are currently unknown features. The role of FGFR1 inhibitors in HRPBC is also unclear.
Methods
FGFR1 amplification (FISH) and overexpression (RNAscope) were investigated in a N = 251 HRPBC patients cohort and the METABRIC cohort; effects on survival and FISH-RNAscope concordance were determined. We generated hormonal deprivation resistant (LTED-R) and FGFR1-overexpressing cell line variants of the ER+ MCF7 and T47-D and the ER+, FGFR1-amplified HCC1428 cell lines. The role of ER, CDK4/6, and/or FGFR1 blockade alone or in combinations in Rb phosphorylation, cell cycle, and survival were studied.
Results
FGFR1 overexpression and amplification was non-concordant in > 20% of the patients, but both were associated to a similar relapse risk (~ 2.5-fold; P < 0.05). FGFR1 amplification or overexpression occurred regardless of the luminal subtype, but the incidence was higher in luminal B (16.3%) than A (6.6%) tumors; P < 0.05. The Kappa index for overexpression and amplification was 0.69 (P < 0.001). Twenty-four per cent of the patients showed either amplification and/or overexpression of FGFR1, what was associated to a hazard ratio for relapse of 2.6 (95% CI 1.44–4.62, P < 0.001). In vitro, hormonal deprivation led to FGFR1 overexpression. Primary FGFR1 amplification, engineered mRNA overexpression, or LTED-R-acquired FGFR1 overexpression led to resistance against hormonotherapy alone or in combination with the CDK4/6 inhibitor palbociclib. Blocking FGFR1 with the kinase-inhibitor rogaratinib led to suppression of Rb phosphorylation, abrogation of the cell cycle, and resistance-reversion in all FGFR1 models.
Conclusions
FGFR1 amplification and overexpression are associated to similar adverse prognosis in hormone-positive breast cancer. Capturing all the patients with adverse prognosis-linked FGFR1 aberrations requires assessing both features. Hormonal deprivation leads to FGFR1 overexpression, and FGFR1 overexpression and/or amplification are associated with resistance to hormonal monotherapy or in combination with palbociclib. Both resistances are reverted with triple ER, CDK4/6, and FGFR1 blockade
Files in this item
Google Scholar:Mouron, Silvana
-
Manso, Luis
-
Caleiras, Eduardo
-
Rodriguez-Peralto, José L.
-
Rueda, Oscar M.
-
Caldas, Carlos
-
Colomer Bosch, Ramón
-
Quintela Fandiño, Miguel Ángel
-
Bueno, María J.